Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (6938)	4/1/1998 2:38:00 PM
From: Jerry Olson	Read Replies (2) \| Respond to of 120523

Jenna I own the YHOO May 85's, paid 4 1/2, their around 13-14 I can make myself to sell the damn things.....:>} hey this crazy stock and sector could keep on truckin right thru eps... We need to identify earnings dates for the big boys...AOL_YHOO_LCOS_ECIT etc..... don't want to lose big gains if any one of these doesn't hit their number......

To: Jenna who wrote (6938)	4/2/1998 12:05:00 AM
From: Jenna	Read Replies (3) \| Respond to of 120523

ICUI,GDT..2 companies in the Medical Products sector that have actually had their EPS UPGRADED in the last 30 days ICUI reports on the 15th and GDT reports on the 14th.. Watch these for optimal entry points. ICUI the EPS was upgraded leaving this company in the top 3% of companies with upgraded EPS. Together with an ERG of 90 and a velocity and acceleration in the 99th percentile of stocks this has a very good chance to beat estimates.. Watch this for the next 10 trading sessions. Can be good for at least 1 entry maybe more... Chart has been deteriorating which is perfect for a surge around the time earnings come out on the 15th. GDT needs no introduction. Sales increasing in Europe. just got government approval to market its MultiLink stent for blood vessels and Ventak AV, an implantable defibrillator and pacemaker. Both products increase the success rate of angioplasty and greatly reduce the risk of heart attack, analysts say. .... Guidant has the dominant position in U.S. health markets. ...MultiLink's recent success has enabled Guidant to take a commanding share of the worldwide stent market, the company says, which is now worth about $1.3 billion. this market should climb 39% in 1998 to $1.8 billion, analysts say. "Further penetration of angioplasty procedures will fuel this growth. GDT reports on April 14.